Laurent Castillo· PfE

Nuanced

More than one third of medicines authorized in Europe are not available in France

Omissions

• The available data refers specifically to New Active Substances (NASs) approved by EMA between 2014-2022, not all medicines authorized in Europe
• The data describes availability across all 27 EU countries with rates ranging from 52% down, but does not specify France's exact position in this range
• Data is from a 2022 report covering approvals through 2022; more recent data may be available
• The figure represents availability rates for a specific subset of innovative medicines rather than the entire pharmaceutical market

Sources

• PrimaryEFPIA - The root cause of unavailability and delay to innovative medicinesDocuments access inequality across EU member states with 10 interrelated factors explaining unavailability and delays in access to innovative medicines
• SecondaryIQVIA Institute - Assessing Availability of New Drugs in Europe, Japan, and the U.S.When all 27 EU countries are considered, the proportion of NASs approved by EMA from 2014-2022 that achieved availability ranges from 52% down, indicating that 48% or more of approved medicines are unavailable in some countries